Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877470 | 0.98 | MMEL1 (0.59) | MMEL1EPHX2UTS2RFAAHMEN1 | |
| SCHEMBL2868858 | 0.87 | MMEL1 (0.51) | MMEL1EPHX2 | |
| SCHEMBL2873259 | 0.85 | MMEL1 (0.47) | MMEL1EPHX2UTS2RFAAHMEN1 | |
| SCHEMBL2707583 | 0.85 | MMEL1 (0.47) | MMEL1EPHX2UTS2RNPC1HPGD | |
| SCHEMBL16975187 | 0.83 | MMEL1 (0.45) | MMEL1EPHX2UTS2RFAAHNPC1 | |
| SCHEMBL15563643 | 0.83 | MME (0.48) | MMEL1EPHX2UTS2RFAAH | |
| SCHEMBL15564105 | 0.81 | MMEL1 (0.42) | MMEL1EPHX2UTS2RFAAHNPC1 | |
| SCHEMBL2873142 | 0.78 | MMEL1 (0.52) | MMEL1EPHX2FAAH | |
| SCHEMBL2877464 | 0.76 | MMEL1 (0.54) | MMEL1EPHX2FAAH | |
| SCHEMBL6684836 | 0.76 | SMN1; SMN2 (0.48) | UTS2RFAAHMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | MMEL1 299/4885EPHX2 1979/4885UTS2R 678/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885EPHX2 1979/4885UTS2R 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.